BrightHeart announces €2 million in seed financing from Sofinnova Partners to improve the detection of fetal heart abnormalities

Paris, France, May, 31, 2023 — BrightHeart, a Paris-based medical technology company developing unique artificial intelligence software focused on improving the detection of congenital heart defects in fetuses, announced today that it has raised €2 million in seed financing from Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan. The funds are being deployed to bolster the development of the BrightHeart technology, prepare its regulatory submission(s), and facilitate the company’s expansion.